Interferon-γ Drives T<sub>reg</sub> Fragility to Promote Anti-tumor Immunity.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 28552348.
- Also identified by DOI 10.1016/j.cell.2017.05.005 and PMC identifier 5509332.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Regulatory T cells (T<sub>regs</sub>) are a barrier to anti-tumor immunity. Neuropilin-1 (Nrp1) is required to maintain intratumoral T<sub>reg</sub> stability and function but is dispensable for peripheral immune tolerance. T<sub>reg</sub>-restricted Nrp1 deletion results in profound tumor resistance due to T<sub>reg</sub> functional fragility. Thus, identifying the basis for Nrp1 dependency and the key drivers of T<sub>reg</sub> fragility could help to improve immunotherapy for human cancer. We show that a high percentage of intratumoral NRP1<sup>+</sup> T<sub>regs</sub> correlates with poor prognosis in melanoma and head and neck squamous cell carcinoma. Using a mouse model of melanoma where Nrp1-deficient (Nrp1<sup>-/-</sup>) and wild-type (Nrp1<sup>+/+</sup>) T<sub>regs</sub> can be assessed in a competitive environment, we find that a high proportion of intratumoral Nrp1<sup>-/-</sup> T<sub>regs</sub> produce interferon-γ (IFNγ), which drives the fragility of surrounding wild-type T<sub>regs</sub>, boosts anti-tumor immunity, and facilitates tumor clearance. We also show that IFNγ-induced T<sub>reg</sub> fragility is required for response to anti-PD1, suggesting that cancer therapies promoting T<sub>reg</sub> fragility may be efficacious.
Medical subject headings
- Carcinoma, Squamous Cell
- Head and Neck Neoplasms
- Interferon-gamma
- Melanoma
- T-Lymphocytes, Regulatory